Juan R Bustillo

List of Publications by Year
in descending order

100 papers	7,764 citations	87401 40 h-index	64407 83 g-index
101 all docs	101 docs citations	101 times ranked	11929 citing authors

#	Article	IF	Citations
1	A <scp>meta‐analysis</scp> of deep brain structural shape and asymmetry abnormalities in 2,833 individuals with schizophrenia compared with 3,929 healthy volunteers via the <scp>ENIGMA Consortium</scp>. Human Brain Mapping, 2022, 43, 352-372.	1.9	39
2	Virtual Ontogeny of Cortical Growth Preceding Mental Illness. Biological Psychiatry, 2022, 92, 299-313.	0.7	11
3	Validation of ketamine as a pharmacological model of thalamic dysconnectivity across the illness course of schizophrenia. Molecular Psychiatry, 2022, 27, 2448-2456.	4.1	15
4	The clinical relevance of gray matter atrophy and microstructural brain changes across the psychosis continuum. Schizophrenia Research, 2021, 229, 12-21.	1.1	4
5	Glutamate connectivity associations converge upon the salience network in schizophrenia and healthy controls. Translational Psychiatry, 2021, 11, 322.	2.4	10
6	Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level. JAMA Psychiatry, 2021, 78, 667.	6.0	72
7	Increased Glutamate Plus Glutamine in the Right Middle Cingulate in Early Schizophrenia but Not in Bipolar Psychosis: A Whole Brain 1H-MRS Study. Frontiers in Psychiatry, 2021, 12, 660850.	1.3	8
8	Characteristics of Hispanics Referred to Coordinated Specialty Care for First-Episode Psychosis and Factors Associated With Enrollment. Psychiatric Services, 2021, 72, 1407-1414.	1.1	4
9	Reward Processing in Novelty Seekers: A Transdiagnostic Psychiatric Imaging Biomarker. Biological Psychiatry, 2021, 90, 529-539.	0.7	25
10	Dentate gyrus volume deficit in schizophrenia. Psychological Medicine, 2020, 50, 1267-1277.	2.7	20
11	Reduced parietal alpha power and psychotic symptoms: Test-retest reliability of resting-state magnetoencephalography in schizophrenia and healthy controls. Schizophrenia Research, 2020, 215, 229-240.	1.1	19
12	Task-induced brain connectivity promotes the detection of individual differences in brain-behavior relationships. NeuroImage, 2020, 207, 116370.	2.1	88
13	M157. A MULTICENTRE STUDY OF 1H-MRS BRAIN GLUTAMATE LEVELS IN SCHIZOPHRENIA; INVESTIGATING THE EFFECT OF ANTIPSYCHOTIC MEDICATION, SYMPTOM SEVERITY AND AGE. Schizophrenia Bulletin, 2020, 46, S195-S196.	2.3	0
14	Differing functional mechanisms underlie cognitive control deficits in psychotic spectrum disorders. Journal of Psychiatry and Neuroscience, 2020, 45, 430-440.	1.4	6
15	Anterior cingulate gamma‐aminobutyric acid concentrations and electroconvulsive therapy. Brain and Behavior, 2020, 10, e01833.	1.0	11
16	Weaker Cerebellocortical Connectivity Within Sensorimotor and Executive Networks in Schizophrenia Compared to Healthy Controls: Relationships with Processing Speed. Brain Connectivity, 2020, 10, 490-503.	0.8	10
17	The relevance of transdiagnostic shared networks to the severity of symptoms and cognitive deficits in schizophrenia: a multimodal brain imaging fusion study. Translational Psychiatry, 2020, 10, 149.	2.4	16
18	Glutamatergic hypo-function in the left superior and middle temporal gyri in early schizophrenia: a data-driven three-dimensional proton spectroscopic imaging study. Neuropsychopharmacology, 2020, 45, 1851-1859.	2.8	8

#	Article	IF	Citations
19	The genetic architecture of the human cerebral cortex. Science, 2020, 367, .	6.0	450
20	Neuroimaging-based Individualized Prediction of Cognition and Behavior for Mental Disorders and Health: Methods and Promises. Biological Psychiatry, 2020, 88, 818-828.	0.7	180
21	Disconnected and Hyperactive: A Replication of Sensorimotor Cortex Abnormalities in Patients With Schizophrenia During Proactive Response Inhibition. Schizophrenia Bulletin, 2019, 45, 552-561.	2.3	6
22	Associations and Heritability of Auditory Encoding, Gray Matter, and Attention in Schizophrenia. Schizophrenia Bulletin, 2019, 45, 859-870.	2.3	8
23	A symptom-based continuum of psychosis explains cognitive and real-world functional deficits better than traditional diagnoses. Schizophrenia Research, 2019, 208, 344-352.	1.1	14
24	Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia. Journal of Affective Disorders, 2019, 246, 745-753.	2.0	19
25	Parallel group ICA+ICA: Joint estimation of linked functional network variability and structural covariation with application to schizophrenia. Human Brain Mapping, 2019, 40, 3795-3809.	1.9	23
26	Salienceâ€“Default Mode Functional Network Connectivity Linked to Positive and Negative Symptoms of Schizophrenia. Schizophrenia Bulletin, 2019, 45, 892-901.	2.3	71
27	Spatial dynamics within and between brain functional domains: A hierarchical approach to study timeâ€varying brain function. Human Brain Mapping, 2019, 40, 1969-1986.	1.9	52
28	The Meaning of Glutamate and the Quest for Biomarkers in the Transition to Psychosis. JAMA Psychiatry, 2019, 76, 115.	6.0	4
29	A framework for linking resting-state chronnectome/genome features in schizophrenia: A pilot study. NeuroImage, 2019, 184, 843-854.	2.1	24
30	Shared Genetic Risk of Schizophrenia and Gray Matter Reduction in 6p22.1. Schizophrenia Bulletin, 2019, 45, 222-232.	2.3	31
31	A working memory related mechanism of auditory hallucinations.. Journal of Abnormal Psychology, 2019, 128, 423-430.	2.0	6
32	Disrupted network cross talk, hippocampal dysfunction and hallucinations in schizophrenia. Schizophrenia Research, 2018, 199, 226-234.	1.1	29
33	Predicting relapse in schizophrenia: Is BDNF a plausible biological marker?. Schizophrenia Research, 2018, 193, 263-268.	1.1	18
34	Functional connectivity during affective mentalizing in criminal offenders with psychotic disorders: Associations with clinical symptoms. Psychiatry Research - Neuroimaging, 2018, 271, 91-99.	0.9	8
35	Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. Biological Psychiatry, 2018, 84, 644-654.	0.7	627
36	Impaired Midline Theta Power and Connectivity During Proactive Cognitive Control in Schizophrenia. Biological Psychiatry, 2018, 84, 675-683.	0.7	43

#	Article	IF	Citations
37	A positive take on schizophrenia negative symptom scales: Converting scores between the SANS, NSA and SDS. Schizophrenia Research, 2018, 201, 113-119.	1.1	3
38	Multimodal neuromarkers in schizophrenia via cognition-guided MRI fusion. Nature Communications, 2018, 9, 3028.	5.8	127
39	Reading the (functional) writing on the (structural) wall: Multimodal fusion of brain structure and function via a deep neural network based translation approach reveals novel impairments in schizophrenia. NeuroImage, 2018, 181, 734-747.	2.1	45
40	An approach to directly link ICA and seed-based functional connectivity: Application to schizophrenia. NeuroImage, 2018, 179, 448-470.	2.1	41
41	Polygenic risk score, genome-wide association, and gene set analyses of cognitive domain deficits in schizophrenia. Schizophrenia Research, 2018, 201, 393-399.	1.1	19
42	Glutamatergic and Neuronal Dysfunction in Gray and White Matter: A Spectroscopic Imaging Study in a Large Schizophrenia Sample. Schizophrenia Bulletin, 2017, 43, sbw122.	2.3	50
43	Modality-Dependent Impact of Hallucinations on Low-Frequency Fluctuations in Schizophrenia. Schizophrenia Bulletin, 2017, 43, sbw093.	2.3	37
44	Predicting individualized clinical measures by a generalized prediction framework and multimodal fusion of MRI data. NeuroImage, 2017, 145, 218-229.	2.1	95
45	Identifying dynamic functional connectivity biomarkers using GIGâ€ICA: Application to schizophrenia, schizoaffective disorder, and psychotic bipolar disorder. Human Brain Mapping, 2017, 38, 2683-2708.	1.9	111
46	By our bootstraps: Comparing methods for measuring auditory 40 Hz steadyâ€state neural activity. Psychophysiology, 2017, 54, 1110-1127.	1.2	20
47	A joint time-frequency analysis of resting-state functional connectivity reveals novel patterns of connectivity shared between or unique to schizophrenia patients and healthy controls. NeuroImage: Clinical, 2017, 15, 761-768.	1.4	39
48	Magnetoencephalographic and functional MRI connectomics in schizophrenia via intra- and inter-network connectivity. NeuroImage, 2017, 145, 96-106.	2.1	42
49	Risk-Conferring Glutamatergic Genes and Brain Glutamate Plus Glutamine in Schizophrenia. Frontiers in Psychiatry, 2017, 8, 79.	1.3	19
50	Biclustered Independent Component Analysis for Complex Biomarker and Subtype Identification from Structural Magnetic Resonance Images in Schizophrenia. Frontiers in Psychiatry, 2017, 8, 179.	1.3	25
51	From Behavioral Facilitation to Inhibition: The Neuronal Correlates of the Orienting and Reorienting of Auditory Attention. Frontiers in Human Neuroscience, 2017, 11, 293.	1.0	6
52	Socio-neuro risk factors for suicidal behavior in criminal offenders with psychotic disorders. Social Cognitive and Affective Neuroscience, 2017, 12, 70-80.	1.5	13
53	Spatial Variance in Resting fMRI Networks of Schizophrenia Patients: An Independent Vector Analysis. Schizophrenia Bulletin, 2016, 42, sbv085.	2.3	24
54	Multimodal Classification of Schizophrenia Patients with MEG and fMRI Data Using Static and Dynamic Connectivity Measures. Frontiers in Neuroscience, 2016, 10, 466.	1.4	68

#	Article	IF	Citations
55	Functional MRI Evaluation of Multiple Neural Networks Underlying Auditory Verbal Hallucinations in Schizophrenia Spectrum Disorders. Frontiers in Psychiatry, 2016, 7, 39.	1.3	19
56	Reproducibility of phase rotation stimulated echo acquisition mode at 3T in schizophrenia: Emphasis on glutamine. Magnetic Resonance in Medicine, 2016, 75, 498-502.	1.9	12
57	Hemodynamic response function abnormalities in schizophrenia during a multisensory detection task. Human Brain Mapping, 2016, 37, 745-755.	1.9	21
58	In Search of Multimodal Neuroimaging Biomarkers of Cognitive Deficits in Schizophrenia. Biological Psychiatry, 2015, 78, 794-804.	0.7	158
59	An fMRI study of multimodal selective attention in schizophrenia. British Journal of Psychiatry, 2015, 207, 420-428.	1.7	25
60	Neuropsychological profile in adult schizophrenia measured with the CMINDS. Psychiatry Research, 2015, 230, 826-834.	1.7	45
61	Patterns of Gray Matter Abnormalities in Schizophrenia Based on an International Mega-analysis. Schizophrenia Bulletin, 2015, 41, 1133-1142.	2.3	183
62	MIR137HG risk variant rs1625579 genotype is related to corpus callosum volume in schizophrenia. Neuroscience Letters, 2015, 602, 44-49.	1.0	18
63	The Paradoxical Relationship between White Matter, Psychopathology and Cognition in Schizophrenia: A Diffusion Tensor and Proton Spectroscopic Imaging Study. Neuropsychopharmacology, 2015, 40, 2248-2257.	2.8	37
64	Relating Intrinsic Low-Frequency BOLD Cortical Oscillations to Cognition in Schizophrenia. Neuropsychopharmacology, 2015, 40, 2705-2714.	2.8	68
65	Comparison of SGA Oral Medications and a Long-Acting Injectable SGA: The PROACTIVE Study. Schizophrenia Bulletin, 2015, 41, 449-459.	2.3	65
66	Visual Hallucinations Are Associated With Hyperconnectivity Between the Amygdala and Visual Cortex in People With a Diagnosis of Schizophrenia. Schizophrenia Bulletin, 2015, 41, 223-232.	2.3	104
67	A Robust Classifier to Distinguish Noise from fMRI Independent Components. PLoS ONE, 2014, 9, e95493.	1.1	24
68	Multisensory stimuli elicit altered oscillatory brain responses at gamma frequencies in patients with schizophrenia. Frontiers in Human Neuroscience, 2014, 8, 788.	1.0	12
69	Increased Glutamine in Patients Undergoing Long-term Treatment for Schizophrenia. JAMA Psychiatry, 2014, 71, 265.	6.0	77
70	Methylation Patterns in Whole Blood Correlate With Symptoms in Schizophrenia Patients. Schizophrenia Bulletin, 2014, 40, 769-776.	2.3	115
71	A multi-scanner study of subcortical brain volume abnormalities in schizophrenia. Psychiatry Research - Neuroimaging, 2014, 222, 10-16.	0.9	39
72	Converting positive and negative symptom scores between PANSS and SAPS/SANS. Schizophrenia Research, 2014, 152, 289-294.	1.1	111

#	Article	IF	Citations
73	Schizophrenia miR-137 Locus Risk Genotype Is Associated with Dorsolateral Prefrontal Cortex Hyperactivation. Biological Psychiatry, 2014, 75, 398-405.	0.7	65
74	The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging and Behavior, 2014, 8, 153-182.	1.1	696
75	Thalamus and posterior temporal lobe show greater inter-network connectivity at rest and across sensory paradigms in schizophrenia. NeuroImage, 2014, 97, 117-126.	2.1	151
76	Genetic influences on cognitive endophenotypes in schizophrenia. Schizophrenia Research, 2014, 156, 71-75.	1.1	14
77	Schizoaffective Disorder in the DSM-5. Schizophrenia Research, 2013, 150, 21-25.	1.1	106
78	Use of proton magnetic resonance spectroscopy in the treatment of psychiatric disorders: a critical update. Dialogues in Clinical Neuroscience, 2013, 15, 329-337.	1.8	50
79	Frontotemporal anatomical connectivity and workingâ€relational memory performance predict everyday functioning in schizophrenia. Psychophysiology, 2012, 49, 1340-1352.	1.2	29
80	Medial-frontal cortex hypometabolism in chronic phencyclidine exposed rats assessed by high resolution magic angle spin 11.7T proton magnetic resonance spectroscopy. Neurochemistry International, 2012, 61, 128-131.	1.9	14
81	Glutamate as a Marker of Cognitive Function in Schizophrenia: A Proton Spectroscopic Imaging Study at 4 Tesla. Biological Psychiatry, 2011, 69, 19-27.	0.7	91
82	Bilateral hippocampal dysfunction in schizophrenia. NeuroImage, 2011, 58, 1158-1168.	2.1	54
83	A Baseline for the Multivariate Comparison of Resting-State Networks. Frontiers in Systems Neuroscience, 2011, 5, 2.	1.2	1,159
84	Unisensory processing and multisensory integration in schizophrenia: A high-density electrical mapping study. Neuropsychologia, 2011, 49, 3178-3187.	0.7	46
85	Altered Expression of Genes Involved in GABAergic Transmission and Neuromodulation of Granule Cell Activity in the Cerebellum of Schizophrenia Patients. American Journal of Psychiatry, 2008, 165, 1594-1603.	4.0	87
86	Proton Magnetic Resonance Spectroscopy During Initial Treatment With Antipsychotic Medication in Schizophrenia. Neuropsychopharmacology, 2008, 33, 2456-2466.	2.8	74
87	Proton echoâ€planar spectroscopic imaging of Jâ€coupled resonances in human brain at 3 and 4 Tesla. Magnetic Resonance in Medicine, 2007, 58, 236-244.	1.9	115
88	What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update. Current Opinion in Psychiatry, 2006, 19, 135-139.	3.1	82
89	Long-Term Treatment of Rats with Haloperidol: Lack of an Effect on Brain N-Acetyl Aspartate Levels. Neuropsychopharmacology, 2006, 31, 751-756.	2.8	40
90	Effects of Ketamine on Anterior Cingulate Glutamate Metabolism in Healthy Humans: A 4-T Proton MRS Study. American Journal of Psychiatry, 2005, 162, 394-396.	4.0	287

#	Article	IF	Citations
91	Treatment of rats with antipsychotic drugs: lack of an effect on brain N-acetyl aspartate levels. Schizophrenia Research, 2004, 66, 31-39.	1.1	24
92	Reproducibility of1H-MRS measurements in schizophrenic patients. Magnetic Resonance in Medicine, 2003, 50, 704-707.	1.9	42
93	Treatment of Weight Gain with Fluoxetine in Olanzapine-Treated Schizophrenic Outpatients. Neuropsychopharmacology, 2003, 28, 527-529.	2.8	59
94	High Choline Concentrations in the Caudate Nucleus in Antipsychotic-Naive Patients With Schizophrenia. American Journal of Psychiatry, 2002, 159, 130-133.	4.0	60
95	Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure. Schizophrenia Research, 2002, 58, 313-321.	1.1	61
96	Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia. Psychiatry Research - Neuroimaging, 2001, 107, 135-149.	0.9	53
97	The Patient with First Episode Psychosis. Journal of Psychiatric Practice, 2001, 7, 123-132.	0.3	0
98	The Psychosocial Treatment of Schizophrenia: An Update. American Journal of Psychiatry, 2001, 158, 163-175.	4.0	346
99	Proton magnetic resonance spectroscopy (H-MRS) studies of schizophrenia. Seminars in Clinical Neuropsychiatry, 2001, 6, 121-130.	1.9	22
100	Schizophrenia: Improving Outcome. Harvard Review of Psychiatry, 1999, 6, 229-240.	0.9	38